EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies

Michel van den Heuvel, Stefan Holdenrieder, Milou Schuurbiers, Daniel Cigoianu, Inga Trulson, Huub van Rossum, David Lang

Tumor Biology · 19.03.2024 · 46 (s1) · S233-S268

DOI: 10.3233/tub-220039 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Tumor Biology, online erschienen am 23.05.2023. Verfasst von Michel van den Heuvel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonology, Radboud University Medical Center - Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The value of serum tumor markers (STMs) in the current therapeutic landscape of lung cancer is unclear. OBJECTIVE: This scoping review gathered evidence of the predictive, prognostic, and monitoring value of STMs for patients with advanced lung cancer receiving immunotherapy (IT) or targeted therapy (TT). METHODS: Literature searches were conducted (cut-off: May 2022) using PubMed and Cochrane CENTRAL databases. Medical professionals advised on the search strategies. RESULTS: Study heterogeneity limited the evidence and inferences from the 36 publications reviewed. While increased baseline levels of serum cytokeratin 19 fragment antigen (CYFRA21-1) and carcinoembryonic antigen (CEA) may predict IT response, results for TT were less clear. For monitoring IT-treated patients, STM panels (including CYFRA21-1, CEA, and neuron-specific enolase) may surpass the power of single analyses to predict non-response. CYFRA21-1 measurement could aid in monitoring TT-treated patients, but the value of CEA in this context requires further investigation. Overall, baseline and dynamic changes in individual or combined STM levels have potential utility to predict treatment outcome and for monitoring of patients with advanced lung cancer. CONCLUSIONS: In advanced lung cancer, STMs provide additional relevant clinical information by predicting treatment outcome, but further standardization and validation is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansCarcinoembryonic AntigenBiomarkers, TumorAntigens, NeoplasmKeratin-19Immunotherapy

Stichwörter der Autor:innen

STMsimmunotherapynon-small cell lung cancersmall cell lung cancertargeted therapy

Substanzen

antigen CYFRA21.1Carcinoembryonic AntigenBiomarkers, TumorAntigens, NeoplasmKeratin-19

Autor:innen und Institutionen

  • Department of Pulmonology, Radboud University Medical Center - Radboud Institute for Molecular Life Sciences, Nijmegen, The Netherlands.
  • Institute for Laboratory Medicine, German Heart Centre, Technical University of Munich, Munich, Germany.
  • Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
  • Department of Laboratory Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Internal Medicine - Pulmonology, Johannes Kepler University Hospital, Linz, Austria.
  • Medical Faculty, Johannes Kepler University, Linz, Austria.

Zitieren

APA

van den Heuvel, M., Holdenrieder, S., Schuurbiers, M., Cigoianu, D., Trulson, I., van Rossum, H., & Lang, D. (2024). Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies. Tumor Biology, 46(s1), S233-S268. https://doi.org/10.3233/tub-220039

Vancouver

van den Heuvel M, Holdenrieder S, Schuurbiers M, Cigoianu D, Trulson I, van Rossum H, et al. Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies. Tumor Biology. 2024;46(s1):S233-S268. doi:10.3233/tub-220039

BibTeX
@article{vandenHeuvel2024,
  author = {van den Heuvel, Michel and Holdenrieder, Stefan and Schuurbiers, Milou and Cigoianu, Daniel and Trulson, Inga and van Rossum, Huub and Lang, David},
  title = {Serum tumor markers for response prediction and monitoring of advanced lung cancer: A review focusing on immunotherapy and targeted therapies},
  journal = {Tumor Biology},
  year = {2024},
  volume = {46},
  number = {s1},
  pages = {S233--S268},
  doi = {10.3233/tub-220039}
}
Kostenlos starten →